130929-57-6 | (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide

Packsize	Purity	Availability	Price	Discounted Price
10mg	95%	in stock	$11.00	$8.00
25mg	95%	in stock	$13.00	$9.00
50mg	95%	in stock	$16.00	$11.00
100mg	95%	in stock	$19.00	$13.00
250mg	95%	in stock	$23.00	$16.00
1g	95%	in stock	$38.00	$27.00
5g	95%	in stock	$125.00	$88.00
25g	95%	in stock	$510.00	$357.00

Description

• Catalog Number: AA15586
• Chemical Name: (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
• CAS Number: 130929-57-6
• Molecular Formula: C14H15N3O5
• Molecular Weight: 305.28599999999994
• MDL Number: MFCD00866580
• SMILES: CCN(C(=O)/C(=C/c1cc(O)c(c(c1)[N+](=O)[O-])O)/C#N)CC

Computed Properties

• Complexity: 500
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 2.1

Literature

• Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20180801

• The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20170801

• Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

  The Lancet. Neurology 20160201

• Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

  Brain research 20130225

• The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.

  Toxicologic pathology 20120801

• Drugs for treating Parkinson disease.

  Nursing 20120701

• Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.

  JAMA 20120606

• Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

  European journal of neurology 20120601

• Finasteride attenuates pathological gambling in patients with Parkinson disease.

  Journal of clinical psychopharmacology 20120601

• Microbial β-glycosylation of entacapone by Cunninghamella echinulata ATCC 9245.

  Journal of bioscience and bioengineering 20120501

• The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.

  European journal of clinical pharmacology 20120301

• Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.

  Expert review of neurotherapeutics 20120201

• Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.

  Clinical neuropharmacology 20120101

• A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.

  Clinical neuropharmacology 20120101

• Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.

  Bioorganic & medicinal chemistry 20111215

• Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

  European journal of neurology 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.

  The International journal of neuroscience 20111101

• Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.

  Drug metabolism and disposition: the biological fate of chemicals 20111101

• Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.

  Hiroshima journal of medical sciences 20110901

• A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.

  Parkinsonism & related disorders 20110801

• Species independence in brain tissue binding using brain homogenates.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20110701

• Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

  Naunyn-Schmiedeberg's archives of pharmacology 20110601

• Role of catechol-O-methyltransferase in the disposition of luteolin in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20110401

• In-line reaction monitoring of entacapone synthesis by Raman spectroscopy and multivariate analysis.

  Journal of pharmaceutical and biomedical analysis 20110325

• Development of characterization methods for entacapone in a pharmaceutical bulk.

  Journal of pharmaceutical and biomedical analysis 20110325

• Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.

  European journal of neurology 20110301

• Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.

  Journal of pharmaceutical and biomedical analysis 20110220

• Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.

  Annals of neurology 20110201

• Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.

  Journal of clinical pharmacology 20110101

• The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

  CNS drugs 20110101

• Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.

  Clinical neuropharmacology 20110101

• The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

  Annals of neurology 20110101

• Identification and categorization of liver toxicity markers induced by a related pair of drugs.

  International journal of molecular sciences 20110101

• A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

  CNS neuroscience & therapeutics 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.

  Parkinsonism & related disorders 20101201

• Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

  International journal of clinical pharmacology and therapeutics 20101101

• Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.

  Nature reviews. Neurology 20101101

• Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20101001

• Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.

  Nuclear medicine and biology 20101001

• LC determination of entacapone in tablets: in vitro dissolution studies.

  Journal of chromatographic science 20101001

• Entacapone: prostate cancer?

  Prescrire international 20101001

• Isolated delusional syndrome in Parkinson's Disease.

  Parkinsonism & related disorders 20100901

• Entacapone.

  Expert opinion on drug metabolism & toxicology 20100801

• Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.

  Current medical research and opinion 20100701

• Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

  Annals of neurology 20100701

• Continuous dopaminergic therapy in Parkinson disease: time to stride back?

  Annals of neurology 20100701

• Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

  The Journal of biological chemistry 20100514

• Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

  Journal of medicinal chemistry 20100422

• Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

  Journal of neural transmission (Vienna, Austria : 1996) 20100301

• The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

  Movement disorders : official journal of the Movement Disorder Society 20100215

• Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.

  Brain research 20100114

• Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20100101

• Mirtazapine-associated urinary retention.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

  Clinical drug investigation 20100101

• Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

  International review of neurobiology 20100101

• LC/MS/MS study for identification of entacapone degradation product obtained by photodegradation kinetics.

  Journal of AOAC International 20100101

• Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.

  Movement disorders : official journal of the Movement Disorder Society 20091215

• Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.

  European journal of neurology 20091201

• Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.

  Movement disorders : official journal of the Movement Disorder Society 20091115

• Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

  Journal of neural transmission (Vienna, Austria : 1996) 20091001

• Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.

  Movement disorders : official journal of the Movement Disorder Society 20090715

• Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.

  Parkinsonism & related disorders 20090701

• Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

  PLoS computational biology 20090701

• Levodopa/carbidopa/entacapone in Parkinson's disease.

  Expert review of neurotherapeutics 20090701

• Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

  European journal of clinical pharmacology 20090501

• Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090415

• Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090315

• Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.

  Neurological research 20090201

• Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.

  European journal of neurology 20090201

• Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

  Movement disorders : official journal of the Movement Disorder Society 20090115

• Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.

  European neurology 20090101

• The liver toxicity biomarker study: phase I design and preliminary results.

  Toxicologic pathology 20090101

• Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.

  Journal of AOAC International 20090101

• Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.

  Clinical drug investigation 20090101

• Establishing the probable mechanism of L-DOPA in Alzheimer's disease management.

  Acta poloniae pharmaceutica 20090101

• Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.

  Journal of the neurological sciences 20081215

• Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.

  Neurobiology of disease 20081201

• Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .

  Current medical research and opinion 20081101

• [Treatment of Parkinson's disease at present and in the future].

  Rinsho shinkeigaku = Clinical neurology 20081101

• Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20080730

• Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.

  European journal of neurology 20080701

• Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20080601

• Homocysteine in restless legs syndrome.

  Sleep medicine 20080501

• The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.

  Psychopharmacology 20080401

• Long-term retention rate of entacapone in the treatment of Parkinson's disease.

  European journal of neurology 20080401

• On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.

  Neuropharmacology 20080401

• Bimodal administration of entacapone in Parkinson's disease patients improves motor control.

  European journal of neurology 20080301

• [Isolated pulmonary hypertension and pergolide].

  Revue neurologique 20080301

• Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

  Clinical neuropharmacology 20080101

• [Entocapone-related lymphocytic colitis].

  Gastroenterologie clinique et biologique 20080101

• Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.

  CNS neuroscience & therapeutics 20080101

• Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

  Clinical neuropharmacology 20080101

• The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.

  Clinical neuropharmacology 20080101

• Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.

  Parkinsonism & related disorders 20071201

• The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

  Experimental neurology 20071201

• Parkinson disease: an incremental challenge.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20071201

• Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function.

  Journal of pharmaceutical sciences 20071101

• Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.

  The Annals of pharmacotherapy 20071101

• Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.

  Movement disorders : official journal of the Movement Disorder Society 20070815

• [Neuromuscular disorders due to adverse effects of antiparkinson agents].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810

• Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.

  Movement disorders : official journal of the Movement Disorder Society 20070730

• Entacapone improves complex movement performance in patients with Parkinson's disease.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20070501

• Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.

  Chemico-biological interactions 20070501

• Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?

  Neurology 20070424

• Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

  Neurology 20070424

• Current pharmacotherapeutic treatment options in Parkinson's disease.

  Disease-a-month : DM 20070401

• Does the preferred orientation of crystallites in tablets affect the intrinsic dissolution?

  Journal of pharmaceutical and biomedical analysis 20070312

• Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.

  European journal of neurology 20070301

• Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20070101

• Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.

  Movement disorders : official journal of the Movement Disorder Society 20070101

• Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.

  European neurology 20070101

• Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.

  Clinical neuropharmacology 20070101

• Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.

  Movement disorders : official journal of the Movement Disorder Society 20061201

• Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20061001

• Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).

  Acta neurologica Scandinavica 20060901

• Long-term care of Parkinson's disease. Strategies for managing 'wearing off' symptom re-emergence and dyskinesias.

  Geriatrics 20060901

• Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

  Journal of the American Medical Directors Association 20060901

• The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.

  Expert opinion on pharmacotherapy 20060701

• Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

  Neurology 20060627

• Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.

  Movement disorders : official journal of the Movement Disorder Society 20060501

• Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.

  Movement disorders : official journal of the Movement Disorder Society 20060301

• Efficacy and safety of high-dose cabergoline in Parkinson's disease.

  Acta neurologica Scandinavica 20060101

• Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.

  Journal of motor behavior 20060101

• Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

  Clinical neuropharmacology 20060101

• Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

  Clinical neuropharmacology 20060101

• The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

  Clinical neuropharmacology 20060101

• Synthesis and biological evaluation of a novel series of 'ortho-nitrated' inhibitors of catechol-O-methyltransferase.

  Journal of medicinal chemistry 20051215

• Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

  Neurology 20051213

• Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.

  Journal of mass spectrometry : JMS 20051201

• High-performance liquid chromatography method for the quantification of entacapone in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050905

• The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20050901

• Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

  Parkinsonism & related disorders 20050901

• Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.

  Analytical biochemistry 20050601

• Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

  Parkinsonism & related disorders 20050601

• Entacapone in the treatment of Parkinson's disease.

  The Lancet. Neurology 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

  Neurologia (Barcelona, Spain) 20050501

• The effect of entacapone on homocysteine levels in Parkinson disease.

  Neurology 20050426

• UDP-glucuronosyltransferases and clinical drug-drug interactions.

  Pharmacology & therapeutics 20050401

• The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401

• Novel pharmacological strategies for motor complications in Parkinson's disease.

  Expert opinion on investigational drugs 20050401

• 'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease.

  Neurology 20050308

• Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

  Movement disorders : official journal of the Movement Disorder Society 20050301

• Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

  Experimental neurology 20050301

• Rasagiline for motor complications in Parkinson's disease.

  Lancet (London, England) 20050301

• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  Lancet (London, England) 20050301

• Improving quality of life in early Parkinson's.

  Health news (Waltham, Mass.) 20050201

• Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

  Movement disorders : official journal of the Movement Disorder Society 20050101

• Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

  Acta neurologica Scandinavica 20050101

• Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.

  Movement disorders : official journal of the Movement Disorder Society 20050101

• Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

  Clinical neuropharmacology 20050101

• Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.

  European neurology 20050101

• Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.

  Journal of medicinal chemistry 20041202

• Assessment of catechol induction and glucuronidation in rat liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20041201

• Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

  Naunyn-Schmiedeberg's archives of pharmacology 20041101

• Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

  The Cochrane database of systematic reviews 20041018

• Clinical advantages of COMT inhibition with entacapone - a review.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Extraneuronal enzymatic degradation of myocardial interstitial norepinephrine in the ischemic region.

  Cardiovascular research 20041001

• Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

  Archives of neurology 20041001

• Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.

  Movement disorders : official journal of the Movement Disorder Society 20040901

• Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.

  European journal of neurology 20040901

• Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

  Journal of neural transmission (Vienna, Austria : 1996) 20040801

• Role of entacapone in later Parkinson's disease not yet established.

  Journal of neurology, neurosurgery, and psychiatry 20040701

• Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

  Expert review of neurotherapeutics 20040701

• Bullous skin eruption associated with entacapone.

  International journal of dermatology 20040601

• Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20040601

• Stalevo for Parkinson's disease.

  The Medical letter on drugs and therapeutics 20040510

• In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.

  Autonomic neuroscience : basic & clinical 20040430

• [Treatment in Parkinson disease].

  Orvosi hetilap 20040411

• An active and water-soluble truncation mutant of the human UDP-glucuronosyltransferase 1A9.

  Molecular pharmacology 20040401

• Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.

  Neuropharmacology 20040301

• Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.

  Journal of neural transmission (Vienna, Austria : 1996) 20040201

• The role of COMT inhibition in the treatment of Parkinson's disease.

  Neurology 20040113

• Safety and tolerability of COMT inhibitors.

  Neurology 20040113

• Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.

  Neurology 20040113

• Continuous dopaminergic stimulation in early and advanced Parkinson's disease.

  Neurology 20040113

• Levodopa/carbidopa/entacapone (Stalevo).

  Neurology 20040113

• The value of post-marketing medication surveys in Parkinson's disease.

  Current medical research and opinion 20040101

• Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.

  Current medical research and opinion 20040101

• [A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20040101

• Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.

  Clinical neuropharmacology 20040101

• Entacapone protects from angiotensin II-induced inflammation and renal injury.

  Journal of hypertension 20031201

• The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001

• Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001

• Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.

  Progress in neuro-psychopharmacology & biological psychiatry 20030901

• Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

  Journal of neurology, neurosurgery, and psychiatry 20030801

• Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20030801

• An artist's view of drug-induced hallucinosis.

  Movement disorders : official journal of the Movement Disorder Society 20030701

• The economic evaluation of pharmacotherapies for Parkinson's disease.

  Parkinsonism & related disorders 20030601

• Absorption rate limit considerations for oral phosphate prodrugs.

  Pharmaceutical research 20030601

• [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].

  MMW Fortschritte der Medizin 20030526

• Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.

  Movement disorders : official journal of the Movement Disorder Society 20030501

• Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.

  Expert opinion on drug safety 20030501

• The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.

  European journal of neurology 20030301

• Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.

  Journal of neural transmission (Vienna, Austria : 1996) 20030301

• Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.

  The Journal of pharmacology and experimental therapeutics 20030201

• Excessive daytime sleepiness and 'sleep attacks' induced by entacapone.

  Fundamental & clinical pharmacology 20030201

• Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.

  Fundamental & clinical pharmacology 20030201

• Position of COMT inhibition in the treatment of Parkinson's disease.

  Advances in neurology 20030101

• Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.

  Parkinsonism & related disorders 20030101

• Entacapone/levodopa/carbidopa combination tablet: Stalevo.

  Drugs in R&D 20030101

• Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.

  Journal of neural transmission (Vienna, Austria : 1996) 20021101

• Entacapone-induced hepatotoxicity and hepatic dysfunction.

  Movement disorders : official journal of the Movement Disorder Society 20021101

• Effects of entacapone and tolcapone on mitochondrial membrane potential.

  European journal of pharmacology 20021018

• Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

  British journal of clinical pharmacology 20021001

• [The usefulness of dopaminergic drugs in traumatic brain injury].

  Revista de neurologia 20020801

• [Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome].

  Der Nervenarzt 20020801

• Catechol-o-methyltransferase and blood pressure in humans.

  Circulation 20020723

• Comparison of electrospray, atmospheric pressure chemical ionization, and atmospheric pressure photoionization in the identification of apomorphine, dobutamine, and entacapone phase II metabolites in biological samples.

  Analytical chemistry 20020715

• Entacapone in the management of Parkinson's disease.

  Expert opinion on pharmacotherapy 20020701

• Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20020701

• Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.

  Pharmacology & toxicology 20020601

• The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.

  Parkinsonism & related disorders 20020601

• Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.

  British journal of clinical pharmacology 20020501

• Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.

  Journal of neural transmission (Vienna, Austria : 1996) 20020501

• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

  Acta neurologica Scandinavica 20020401

• Design and synthesis of a novel L-dopa-entacapone codrug.

  Journal of medicinal chemistry 20020314

• Entacapone in restless legs syndrome.

  Movement disorders : official journal of the Movement Disorder Society 20020301

• COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.

  Neurology 20020226

• Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.

  Journal of medicinal chemistry 20020131

• Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.

  Journal of neural transmission (Vienna, Austria : 1996) 20020101

• Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

  PharmacoEconomics 20020101

• COMT inhibitors: management of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20020101

• Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.

  The Journal of pharmacy and pharmacology 20011101

• Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats.

  Toxicological sciences : an official journal of the Society of Toxicology 20010901

• Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Biomedical sciences and applications 20010815

• L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.

  Psychopharmacology 20010801

• Current advances in Parkinson's disease.

  Trends in neurosciences 20010701

• Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

  Clinical therapeutics 20010601

• [Parkinson disease. Value of COMT inhibitors is verified].

  MMW Fortschritte der Medizin 20010503

• D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.

  Kidney international 20010501

• Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.

  Synapse (New York, N.Y.) 20010401

• [Parkinson's disease].

  Presse medicale (Paris, France : 1983) 20010303

• [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].

  Neurologia (Barcelona, Spain) 20010201

• Possible applications for dopaminergic agents following traumatic brain injury: part 2.

  The Journal of head trauma rehabilitation 20010201

• Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.

  European neurology 20010101

• Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.

  Clinical neuropharmacology 20010101

• Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.

  European journal of clinical pharmacology 20010101

• The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.

  Seminars in neurology 20010101

• The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

  Clinical neuropharmacology 20010101

• Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

  European neurology 20010101

• Twelve-month safety of entacapone in patients with Parkinson's disease.

  European journal of neurology 20010101

• Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.

  Clinical neuropharmacology 20010101

• Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20010101

• COMT inhibition and safety.

  Functional neurology 20010101

• [Dopaminergic agonists in the treatment of Parkinson's disease].

  Revue medicale de Bruxelles 20001201

• Entacapone.

  The Annals of pharmacotherapy 20000901

• Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

  Drugs 20000601

• Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.

  The European journal of neuroscience 20000301

• Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

  Biochemistry 19950404

• Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.

  European journal of pharmacology 19950214